Glenview Trust Co bought a new stake in shares of Becton, Dickinson and Company (NYSE:BDX – Free Report) in the second quarter, according to its most recent Form 13F filing with the SEC. The fund bought 72,242 shares of the medical instruments supplier’s stock, valued at approximately $10,932,000.
Several other large investors also recently made changes to their positions in BDX. Imprint Wealth LLC acquired a new position in shares of Becton, Dickinson and Company in the 3rd quarter worth approximately $25,000. SHP Wealth Management purchased a new stake in shares of Becton, Dickinson and Company in the fourth quarter valued at $26,000. Meeder Asset Management Inc. lifted its stake in Becton, Dickinson and Company by 152.2% in the 1st quarter. Meeder Asset Management Inc. now owns 169 shares of the medical instruments supplier’s stock worth $27,000 after acquiring an additional 102 shares in the last quarter. Prosperity Bancshares Inc acquired a new stake in shares of Becton, Dickinson and Company during the fourth quarter worth approximately $29,000. Finally, Main Street Group LTD purchased a new position in shares of Becton, Dickinson and Company during the 1st quarter valued at $29,000. Institutional investors and hedge funds own 86.97% of the company’s stock.
Becton, Dickinson and Company Price Performance
Shares of Becton, Dickinson and Company stock opened at $188.11 on Friday. The stock has a market capitalization of $51.83 billion, a price-to-earnings ratio of 56.66, a P/E/G ratio of 13.41 and a beta of 0.19. The firm’s 50-day moving average price is $165.23 and its two-hundred day moving average price is $160.33. The company has a current ratio of 0.87, a quick ratio of 0.51 and a debt-to-equity ratio of 0.55. Becton, Dickinson and Company has a 1-year low of $127.59 and a 1-year high of $193.07.
Becton, Dickinson and Company Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Wednesday, September 30th. Shareholders of record on Wednesday, September 9th will be issued a $1.05 dividend. The ex-dividend date is Wednesday, September 9th. This represents a $4.20 annualized dividend and a yield of 2.2%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 126.51%.
Insider Activity
In other news, EVP Michael David Garrison sold 1,100 shares of the business’s stock in a transaction on Wednesday, June 24th. The shares were sold at an average price of $145.66, for a total value of $160,226.00. Following the completion of the transaction, the executive vice president owned 13,172 shares of the company’s stock, valued at $1,918,633.52. The trade was a 7.71% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Feld sold 165 shares of the company’s stock in a transaction on Wednesday, August 26th. The shares were sold at an average price of $188.49, for a total transaction of $31,100.85. Following the completion of the sale, the executive vice president owned 19,720 shares of the company’s stock, valued at approximately $3,717,022.80. This represents a 0.83% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 11,869 shares of company stock valued at $1,994,719. 0.40% of the stock is owned by company insiders.
Wall Street Analyst Weigh In
A number of equities analysts recently commented on BDX shares. TD Cowen increased their price objective on Becton, Dickinson and Company from $163.00 to $182.00 and gave the stock a “hold” rating in a report on Wednesday, August 5th. Royal Bank Of Canada increased their target price on Becton, Dickinson and Company from $180.00 to $190.00 and gave the company a “sector perform” rating in a research note on Thursday, August 13th. Piper Sandler lifted their price target on Becton, Dickinson and Company from $161.00 to $175.00 and gave the stock a “neutral” rating in a research report on Friday, August 7th. UBS Group assumed coverage on Becton, Dickinson and Company in a report on Tuesday, July 28th. They set a “buy” rating and a $190.00 price target for the company. Finally, Barclays raised their price objective on shares of Becton, Dickinson and Company from $202.00 to $204.00 and gave the stock an “overweight” rating in a research note on Monday, May 11th. Eight research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $185.67.
Read Our Latest Analysis on Becton, Dickinson and Company
About Becton, Dickinson and Company
Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.
BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.
Read More
- Five stocks we like better than Becton, Dickinson and Company
- Nutanix’s Rally Has a Bigger Story Than Earnings as AMD’s AI Bet Takes Shape
- SEC Probe Puts Wall Street Leverage Risk Back in Focus
- A Bearish-Dollar Options Surge Raises the Stakes for Warsh at Jackson Hole
- Five Below’s Turnaround Is Working—But Has the Stock Run Too Far?
Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.
